Catalent Acquires Exclusive Worldwide rights to Lyopan® Fast-Dissolve Technology
SOMERSET, NJ, February 15, 2011 - Catalent Pharma Solutions, the world's leading provider of advanced oral drug delivery technologies and solutions, announced that it has entered into a license agreement with Pantec AG for the exclusive worldwide development rights to the Lyopan® fast-dissolve technology for healthcare products.
"We are pleased to add the Lyopan® technology to Catalent's oral dose technology offering, which will enable us to provide our pharmaceutical partners with an enhanced choice of drug delivery technologies to improve the performance of their treatments," stated Ian Muir, Ph.D., President, Modified Release Technologies for Catalent. "The Lyopan® technology is ideally suited to deliver a wide dose range of active pharmaceutical ingredients in a fast-dissolve tablet. These are key considerations for situations where patient adherence, ease of swallowing and lack of access to water are important issues to address."
Lyopan® is a proprietary technology for development and manufacture of fast-dissolve lyophilized tablets, including over-the-counter (OTC) products such as allergy treatments or travel medications. Lyopan® also requires significantly less water than existing technology, an advantage that helps reduce energy consumption, sublimation and drying time. As a result of these advanced characteristics, Lyopan® technology offers the potential for improved taste-masking capabilities and may increase the range of drugs and consumer products that can be used in a fast dissolve dosage form.
The acquisition of Lyopan® technology is the latest example of Catalent's ongoing investment in advanced oral dose solutions and novel technologies. It advances Catalent's oral dose capabilities, potentially enabling the delivery of improved, compliance-enhancing treatments across a broad range of applications, including central nervous system drugs, allergy medications, and dosage forms for pediatric and geriatric populations. Additionally, Lyopan® technology lends itself easily to the development of both prescription and OTC products.
"With its long history of developing lyophilized fast-dissolve products, Catalent is the ideal partner to launch our innovative Lyopan® technology," commented Hans Peter Rohrer, Chairman of Pantec.
The acquisition of Lyopan® technology also has clear synergies with several of Catalent's existing technologies, such as Zydis® fast dissolve, a unique, freeze-dried oral solid dosage form that disperses instantly in the mouth, without requiring water.
Catalent's Modified Release Technologies business provides the most oral dosage-form solutions with innovative, advanced formulation and process technologies, including tablets, capsules and other formulations for sustained or modified release. Catalent has a proven record of introducing advanced orally disintegrating tablet (ODT) technologies to the market, including Zydis® fast dissolve.
Pantec is the owner of the proprietary Lyopan® fast-dissolve technology. Pantec is a privately held development company based in Switzerland.
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,000 people at 28 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ.